@TheAbSociety Profile picture

The Antibody Society

@TheAbSociety

Similar User
Oxford Protein Informatics Group (OPIG) photo

@OPIGlets

ImmunoInformatics photo

@immuno_inform

iReceptor Gateway photo

@ireceptorgw

airr_community photo

@airr_community

Geir Kjetil Sandve photo

@SandveGeir

Antibody Therapeutics photo

@AntibodyT

PipeBio (now Benchling) photo

@pipe_bio

GreiffLab 💻🔬💊 photo

@victorgreiff

Judy Savitskaya photo

@heyjudka

immuneML photo

@immuneml

Matt Raybould photo

@mijr12

Eve Richardson photo

@EveRichardson20

Steven Kleinstein 🖥 photo

@skleinstein

Cardiology Today photo

@CardiologyToday

Blood Journal photo

@BloodJournal

Merus Receives FDA extension of PDUFA for zenocutuzumab - Merus ir.merus.nl/news-releases/…


@hifibio⁩ Therapeutics Receives FDA Clearance of IND Application for HFB200604, a Best-in-Class BTLA Agonist Antibody for the Treatment of Inflammatory and Immunology Diseases  - HiFiBio Therapeutics hifibio.com/hifibio-therap…


@Merck⁩ Enters into Exclusive Global License for LM-299, An Investigational Anti-PD-1/VEGF Bispecific Antibody from LaNova Medicines Ltd. - Merck.com merck.com/news/merck-ent…


Aditum Bio and Leads Biolabs Announce the Formation of Oblenio Bio to Develop a Tri-Specific T-Cell Engager for Autoimmune Disorders prnewswire.com/news-releases/…


Listen to our Podcasts: Antibody News | The Antibody Society theantibodysociety.podbean.com


The Antibody Society Reposted

#MichelsonPrizes recipient Dr. Jenna Guthmiller has been selected as the 2024 James S. Huston Antibody Science Talent Award Recipient. The award recognizes and encourages upcoming antibody engineering and therapeutics scientists. Recipients are recognized for making important…


U.S. FDA Approves Pfizer’s HYMPAVZI™ (marstacimab-hncq) for the Treatment of Adults and Adolescents with Hemophilia A or B Without Inhibitors | ⁦@pfizerpfizer.com/news/press-rel…


@biogen⁩ Receives U.S. FDA Breakthrough Therapy Designation for Felzartamab for the Treatment of Antibody-Mediated Rejection in Kidney Transplant Recipients | Biogen investors.biogen.com/news-releases/…


First Patient dosed with NILK-2401 in Phase I clinical trial lightchainbio.com/news/first-pat…


Shattuck Labs | Shattuck Labs Provides Company Update and Announces SL-325, a First-In-Class Death Receptor 3 (DR3) Antagonist Targeting the TL1A/DR3 Signaling Pathway ir.shattucklabs.com/investors/news…


Antiverse Raises £3.5M ($4.6M) to Advance Generative AI Antibody Design Platform antiverse.substack.com/p/antiverse-ra…


UPB IPO News - Respiratory disorder biotech Upstream Bio sets terms for $200 million IPO | Renaissance Capital renaissancecapital.com/IPO-Center/New…


ImmunoPrecise Subsidiary Signs Material Transfer Agreement with Biotheus - ⁦@ImmunoPrecise⁩ Antibodies Ltd. ir.ipatherapeutics.com/news/news-rele…


Regeneron Provides Update on Biologics License Application for Linvoseltamab | Regeneron Pharmaceuticals Inc. investor.regeneron.com/news-releases/…


Johnson & Johnson seeks first approval of nipocalimab to treat broadest population living with antibody positive generalized myasthenia gravis prnewswire.com/news-releases/…


FDA Grants Fast Track Designation for Bexmarilimab - Faron Pharmaceuticals Oy news.cision.com/faron-pharmace…


GSK receives US FDA Breakthrough Therapy Designation for its B7-H3-targeted antibody-drug conjugate in relapsed or refractory extensive-stage small-cell lung cancer | GSK gsk.com/en-gb/media/pr…


Apogee Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of APG990, its Novel Half-Life Extended OX40L Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Diseases | Apogee Therapeutics, Inc. investors.apogeetherapeutics.com/news-releases/…


Loading...

Something went wrong.


Something went wrong.